The mTOR Pathway Independent Function of NPRL2 in the Regulation of S-Phase DNA Damage Response

Clemens An, Yang Peng, Wei Zhao, Lulu Wang, Jianfeng Shen, Zhenlin Ju, Hui-Ju Hsieh, Timothy Yap, Gordon Mills, and Guang Peng

Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

Abstract:
We conducted a genetic screen to systematically identify molecular determinants of S-phase DNA damage response. We identified that NPRL2, a subunit of the GATOR1 complex, regulates S-DDR in an mTOR-pathway-independent fashion. Loss of NPRL2 reduces CHK1 protein stability and leads to defective S-DDR. NPRL2 deficiency enhances anti-tumor immunity through activation of DNA sensor STING-mediated innate immune response. We identify that NPRL2 is a key regulator of genome maintenance and anti-tumor immunity.

Introduction:
• The GATOR1 complex functions as a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1) by activating RagA GTPase
• NPRL2 was a key mediator of sensitivity to irinotecan treatment, a topoisomerase I inhibitor, which suggests a possible role in S-phase DNA damage response.
• Mismatch repair (MMR) deficiency activates adaptive immune response and predicts responses of tumors to immune checkpoint blockade agents.
• NPRL2 expression was significantly lower in basal-like breast cancer.
• Reduced mRNA expression of NPRL2 correlated strongly with poor cancer patient survival.
• In melanoma and renal carcinoma studies, patients with low-NPRL2 expressing tumors showed better response to immune checkpoint blockade (PD-1/PD-L1).

Methods/Techniques:
Genomic Screening of S-Phase defective genes. 10169 genes were used to generate irinotecan sensitivity signatures after in-house normalization to average negative controls of each plate, comparison between average of high and average of medium/low cell lines were conducted to generate genomic similarity with Pan-Cancer Irinotecan sensitivity marker SLFN11.
Cell Culture. The breast and ovarian cancer cell lines were kindly provided by Dr. Gordon B. Mills laboratory. The 293T and H3578T cells were maintained in DMEM. The other cell lines were maintained in RPMI1640 medium.
Multiplexed IHC staining. Tumor tissue from 4T1 underwent multiplexed immunofluorescence following the manufacturer’s instruction (PerkinElmer). The following antibodies were used for IHC: anti-mouse PD-L1, anti-CD8, anti-STING, and anti-phospho-IRF3.
TIL scoring analysis and mutation load analysis. We analyzed the correlation of NPRL2 mRNA level and the immune signature scores and conducted FDR-based multiple testing correcting.
In Vivo Mouse Models. 4T1 breast cancer cells were injected into the mammary pads of 6-8 weeks old female mice per group. Tumor progression was monitored once per week.

Results:

Discussion:
• The data suggests that the effect of NPRL2 on CHK1 protein stability is independent of its role in regulating mTOR signaling.
• DNA replication, recombination, and repair cell cycle were among the top networks of proteins interacting with NPRL2, consistent with its role in S-DDR.
• Our findings demonstrate that NPRL2 deficiency promotes an innate immune response, suggesting that NPRL2 could determine immune responsiveness and may predict responses to immune checkpoint blockade in tumors with low mutation load.
• Results show that defective S-DDR as a tumor-intrinsic mechanism that activates the STING pathway and sensitizes tumors to anti-PD-L1 treatment.

Acknowledgements:
I thank Dr. Guang Peng, Dr. Peng Yang, and Dr. Yanting Zhang for their valuable assistance and training. This project was supported by the First-Year Medical Student Summer Program, NCI Cancer Center Support Grant, Department of Defense Grant, and CPRIT grant. Finally, I would like to thank my fellow co-interns for the support, compassion, and dedication they have in cancer research.

References: